GlobalData Plc
  • Press Release

    Lupus R&D landscape set to be dominated by partnerships between Big Pharma and small biotech

The lupus market, which is set to reach $3.2 billion by 2025 and has historically been dominated by inexpensive generic drugs, will see a future R&D landscape dominated by partnerships among Big Pharma and small biotech, according to GlobalData, a recognized leader in providing business information and analytics.

GlobalData’s report states that drug development for systemic lupus erythematosus (SLE) and lupus nephritis (LN) is associated with high risk of late-stage failures, but also high rewards in terms of commercial potential. Given the enormous challenges and hurdles faced by companies in the past when developing products for the management of SLE and LN, pharmaceutical companies are pursuing a range of different strategies in order to build their product portfolios.

Sebastian S. Gehrke, Ph.D., Healthcare Analyst for GlobalData, explains: “Companies are focusing on a very narrow patient population in the SLE market. Clinical trials tend to recruit treatment-naïve SLE patients with high disease activity, as this patient population has been shown to have the greatest measurable benefit for a possible clinical outcome.”

“The high risk associated with late-stage failure means that the burden of development is mostly in the hands of small biotechnology companies such as Anthera, Aurinia, and ImmuPharma, or is shared among the larger players by strategic partnerships. For example, anifrolumab is developed by AstraZeneca and licensed from Bristol-Myers Squibb (BMS), and Orencia is co-developed by BMS and Ono.”

While in the past LN pipeline drugs were developed to rescue a potential pipeline product developed for SLE or to seek label extension for drugs already approved for the disease such as GlaxoSmithKline’s Benlysta, GlobalData anticipates that a new corporate strategy in the lupus market is emerging, where development programs are aimed specifically at approval for LN (Aurinia’s voclosporin), or aimed at both SLE and LN (Anthera’s blisibimod and AstraZeneca’s anifrolumab).

While, GlobalData expects anifrolumab to be the market leader in LN by 2025, with annual sales of $144.9 million, a tremendous amount of unmet need will still be unaddressed, giving other players plenty of opportunity to enter the field.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…